CardiaCare recently announced it signed a strategic licensing agreement with Dr. Reddy’s Laboratories to further develop CardiaCare’s wearable atrial fibrillation treatment device.
Through the agreement, Dr. Reddy’s Laboratories will lead necessary clinical studies for CardiaCare to receive regulatory clearance in India.
CardiaCare is developing a non-invasive, personalized neuromodulation wearable for atrial fibrillation treatment. It will receive undisclosed upfront and royalty payments, while Dr. Reddy’s will manage commercialization and distribution in India.
The agreement will make India the first market to offer a home-care digital therapeutic for AFib patients, according to the news release posted Dec. 15. Headquartered in Hyderabad, Dr. Reddy’s had $2.8 billion in revenue in its most recent fiscal year. It’s one of a number of major pharmaceutical companies based out of India.